bioRxiv ScienceSearch

Biology subjects

Rabizadeh, S.

Publications and source records attributed to Rabizadeh, S..

2 recordsLinked to original sources

Identification of an immune gene expression signature associated with favorable clinical features in Treg-enriched patient tumor samples

Immune heterogeneity within the tumor microenvironment undoubtedly adds several layers of complexity to our understanding of drug sensitivity and patient prognosis across various cancer types. Within the tumor microenvironment, immunogenicity is a favorable clinical feature in part driven by the antitumor activity of CD8+ T cells. However, tumors often inhibit this antitumor activity by exploiting the suppressive function of Regulatory T cells (Tregs), thus suppressing the adaptive immune response. Despite the seemingly intuitive immunosuppressive biology of Tregs, prognostic studies have produced contradictory results regarding the relationship between Treg enrichment and survival. We therefore analyzed RNA-seq data of Treg-enriched tumor samples to derive a pan-cancer gene signature able to help reconcile the inconsistent results of Treg studies, by better understanding the variable clinical association of Tregs across alternative tumor contexts. We show that increased expression of a 32-gene signature in Treg-enriched tumor samples (n=135) is able to distinguish a cohort of patients associated with chemosensitivity and overall survival This cohort is also enriched for CD8+ T cell abundance, as well as the antitumor M1 macrophage subtype. With a subsequent validation in a larger TCGA pool of Treg-enriched patients (n = 626), our results reveal a gene signature able to produce unsupervised clusters of Treg-enriched patients, with one cluster of patients uniquely representative of an immunogenic tumor microenvironment. Ultimately, these results support the proposed gene signature as a putative biomarker to identify certain Treg-enriched patients with immunogenic tumors that are more likely to be associated with features of favorable clinical outcome.

cancer biology

Predicting DNA accessibility in the pan-cancer tumor genome using RNA-seq, WGS, and deep learning

DNA accessibility, chromatin regulation, and genome methylation are key drivers of transcriptional events promoting tumor growth. However, understanding the impact of DNA sequence data on transcriptional regulation of gene expression is a challenge, particularly in noncoding regions of the genome. Recently, neural networks have been used to effectively predict DNA accessibility in multiple specific cell types [14]. These models make it possible to explore the impact of mutations on DNA accessibility and transcriptional regulation.\n\nOur work first improved on prior cell-specific accessibility prediction, obtaining a mean receiver operating characteristic (ROC) area under the curve (AUC) = 0.910 and mean precision-recall (PR) AUC = 0.605, compared to the previous mean ROC AUC = 0.895 and mean PR AUC = 0.561 [14].\n\nOur key contribution extended the model to enable accessibility predictions on any new sample for which RNA-seq data is available, without requiring cell-type-specific DNase-seq data for re-training. This new model obtained overall PR AUC = 0.621 and ROC AUC = 0.897 when applied across whole genomes of new samples whose biotypes were held out from training, and PR AUC = 0.725 and ROC AUC = 0.913 on randomly held out new samples whose biotypes were allowed to overlap with training.\n\nMore significantly, we showed that for promoter and promoter flank regions of the genome our model predicts accessibility to high reliability, achieving PR AUC = 0.839 in held out biotypes and PR AUC = 0.911 in randomly held out samples.\n\nThis performance is not sensitive to whether the promoter and flank regions fall within genes used in the input RNA-seq expression vector.\n\nFinally, we utilize this tool to investigate, for the first time, promoter accessibility patterns across several cohorts from The Cancer Genome Atlas (TCGA) [27].

bioinformatics